Companies · Biotechnology

Lodestone Biomedical, LLC

Lebanon · Biotechnology

Diligence memoA one-page analyst read on Lodestone Biomedical, LLC — recommendation, valuation, rhythm, risks.
$1.1M
Total raised · real
3
Rounds
4.1×
Latest step-up
Top 81%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Dec 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Lodestone Biomedical, LLC looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.66× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Lodestone Biomedical, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.0 yr record
Peak capital year was 2017 with $550K across 1 filings.
Market position
ahead of 20% of Biotechnology peers
Capital scale is ahead of 20% of Biotechnology peers; modeled value is above 19% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $550K across 1 filings.
  • Largest single filing was $550K on 2017-07-06.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Lodestone Biomedical, LLC is one of 4293 Biotechnology companies tracked from Lebanon. By capital raised it ranks in the long tail (ahead of 20% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2021-12-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2017-07-06 Raised $550K (real) Modeled valuation $30M (est)$550K$30MPre-Seed2017Pre-Seed · 2020-03-17 Raised $110K (real) Modeled valuation $6.1M (est)$110K$6.1MPre-Seed2020Pre-Seed · 2021-12-01 Raised $450K (real) Modeled valuation $10M (est)$450K$10MPre-Seed2021+$110K+$450KCumulative $1.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$550K · 2017
Pre-Seed extension$110K · 2020
Pre-Seed extension$450K · 2021

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$10.3M
Base estimate est.
$240K
Conservative case
$76.0M
Upside case
$2.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $30.4M · 2017-07-062017Pre-Seed · modeled $6.1M · 2020-03-17Pre-Seed · modeled $10.3M · 2021-12-012021
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
4.6 yr
Elapsed time used
4.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
26 mo
Avg between rounds
$252K/yr
Capital velocity
9.0 yr
On record since
2017
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.2× of median
This company$1.1M
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.1× above median
This company$450K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$10.3M
Sector median$64.2M

Raised more than 20% of sector peers (real $). Modeled value above 19% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #103 of 156.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Crimson BioPharm Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Pinpoint Therapeutics Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Transplant Logistics & Informatics Llc · Pre-Seed Raised $1.0M · modeled $55.2M (est)RNAissance AG LLC · Pre-Seed Raised $990K · modeled $54.7M (est)Pylum Biosciences, Inc. · Pre-Seed Raised $990K · modeled $54.7M (est)NanoTomer, Inc. · Pre-Seed Raised $950K · modeled $52.4M (est)Morphogenyx Inc · Pre-Seed Raised $4.0M · modeled $51.0M (est)Ntxbio, Llc · Pre-Seed Raised $1.9M · modeled $50.5M (est)Oncospace, Inc. · Pre-Seed Raised $900K · modeled $49.7M (est)Cerflux, Inc. · Pre-Seed Raised $880K · modeled $48.6M (est)KDx Diagnostics, Inc. · Pre-Seed Raised $1.7M · modeled $45.3M (est)Sensorygen, Inc. · Pre-Seed Raised $814K · modeled $44.9M (est)Lodestone Biomedical, LLC (this company) Raised $1.1M · modeled $10.3M (est)Lodestone Biomedical, LLC
CompanyStageRaised · realValue · estvs peer med.
Crimson BioPharm Inc.Pre-Seed$1.0M$55.2M3.54×
Pinpoint Therapeutics Inc.Pre-Seed$1.0M$55.2M3.54×
Transplant Logistics & Informatics LlcPre-Seed$1.0M$55.2M3.54×
RNAissance AG LLCPre-Seed$990K$54.7M3.51×
Pylum Biosciences, Inc.Pre-Seed$990K$54.7M3.51×
NanoTomer, Inc.Pre-Seed$950K$52.4M3.36×
Morphogenyx IncPre-Seed$4.0M$51.0M3.27×
Ntxbio, LlcPre-Seed$1.9M$50.5M3.24×
Oncospace, Inc.Pre-Seed$900K$49.7M3.19×
Cerflux, Inc.Pre-Seed$880K$48.6M3.12×
KDx Diagnostics, Inc.Pre-Seed$1.7M$45.3M2.90×
Sensorygen, Inc.Pre-Seed$814K$44.9M2.88×
Lodestone Biomedical, LLC this companyPre-Seed$1.1M$10.3M0.66×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$550K2017-07-06$3.1M$30.4M90%
Pre-Seed$110K2020-03-17$611K$6.1M90%
Pre-Seed$450K2021-12-01$2.5M$10.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$550K2017-07-06
    • First recorded raise — entered as Pre-Seed.
    • 7 investors on this round.
  2. Pre-Seed$110K2020-03-17
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 5.0× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  3. Pre-Seed$450K2021-12-01
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • 6 investors on this round.
Intelligence
2024 ~Q1
Modeled next raise · ~26mo cadence
$1.4M
Modeled next size est.range $878K$2.2M
4.1×
Last step-up
$252K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Lidia Valdes2017-07
Solomon Diamond2017-07
Registry & provenance

Lodestone Biomedical, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1710677
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Geneticure Inc.BiotechnologyPre-Seed$1.1M$11.0Msame sector · same stage
Miraculins IncBiotechnologyPre-Seed$1.1M$11.9Msame sector · same stage
Protege Biomedical, LLCBiotechnologyPre-Seed$1.1M$9.7Msame sector · same stage
ICaPath, Inc.BiotechnologyPre-Seed$1.1M$11.2Msame sector · same stage
Creative BioTherapeutics LLCBiotechnologyPre-Seed$1.0M$7.5Msame sector · same stage
Tractus CorpBiotechnologyPre-Seed$1.0M$10.4Msame sector · same stage
Healthy Humming, LLCBiotechnologyPre-Seed$1.2M$7.2Msame sector · same stage
Meru Biotechnologies, Inc.BiotechnologyPre-Seed$1.2M$9.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Biodesix IncBiotechnologySeries B$635.0M87%
CytoBioscience, Inc.BiotechnologySeries B$60.7M85%
Jupiter Biomedical Research, Inc.BiotechnologyPre-Seed$844K84%
Shoreline Biosciences, Inc.BiotechnologySeries D+$3.7B84%
Drug Delivery Company, LLCBiotechnologySeed$3.1M84%
Cellular Biomedicine Group, Inc.BiotechnologySeries B$1.2B84%
BirchBioMed Inc.BiotechnologySeries A$571K84%
Mosaic Biosciences, Inc.BiotechnologySeries A$176.4M84%
Frequently asked
How much funding has Lodestone Biomedical, LLC raised?
Lodestone Biomedical, LLC has raised approximately $1.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Lodestone Biomedical, LLC's estimated valuation?
Provath's modeled valuation for Lodestone Biomedical, LLC is approximately $10.3M (modeled range $240K–$76.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Lodestone Biomedical, LLC at?
Lodestone Biomedical, LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Dec 01.
What does Lodestone Biomedical, LLC do and where is it based?
Lodestone Biomedical, LLC operates in the Biotechnology sector, based in Lebanon.
Explore related

See where Lodestone Biomedical, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Lodestone Biomedical, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.